Skip to content
drillr.ai

KALV

KalVista Pharmaceuticals, Inc.

NASDAQ · USHealthcareBiotechnology
$27.00+0.00%

Price as of Jun 12, 2026

KALV news

KalVista Pharmaceuticals, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

    Chiesi Group Completes Acquisition of KalVista Pharmaceuticals Positioned to Expand Patient Access and Accelerate Impact in Rare Diseases Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. (“KalVista”). KalVista is now part of Chiesi Group and will contribute to the growth of the Rare Diseases business unit, focused on research, development and commercializa

    Business Wire ·

  2. Halper Sadeh LLC is Investigating Whether RLYB, KALV, INM, TMHC are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Halpe

    Globe Newswire ·

  3. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Taylor Morrison Home Corporation (NYSE - TMHC), Rallybio Corporation (Nasdaq – RLYB), InMed Pharmaceuticals, Inc. (Nasdaq – INM), KalVista Pharmaceuticals, Inc. (Nasdaq – KALV)

    BALA CYNWYD, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Taylor Morrison Home Corporation (NYSE - TMHC) Under the terms of the Merger Agreement, Taylor Morrison will be acquired by Berkshire Hathaway to acquire Taylor

    Globe Newswire ·

  4. Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?

    Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 19, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible

    PR Newswire ·

  5. KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

    KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com%2F&esheet=54538698&newsitemid=20260519649071&lan=en-US&anchor=Kahn+Swick+%26amp%3B+Foti&index=1&md5=fa21bffa628f2caf8df5b42a85e403e9) , LLC (“KSF”)

    Business Wire ·

  6. $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—MDV, GBTG, KALV, and LEGT

    NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde (https://www.globenewswire.com/Tracker?data=Nzfi7S-tCydErxKZ7f4Kx8VmoMmLKfYhKv8GfkOZHfzuqI07GzpKPMo5sqA5jD9mH3--2hHI2bb8KNDM1rEqjQABGxyI9kZXdhu7GoJYgJBPnccTAHNlV7EoU6UGOlUlfJ7TlsT2k7KZtdrnjLZxxGwo-pAr3YkIgV9ojlsTZYoLGoaFIMJfmimwHLCp79PdQEoRGKAH4ZfGAutJFb0IkQ==) with Monteverde & Associates PC (https://www.globenewswire.com/Tracker?data=AL-uM_9QoEnapvx2yYAutNts8pSSJGBlTGPOgpcBLb7_LaFOJiveVazjiS3VwcrVttvGmBXExMw3qzE1

    Globe Newswire ·

  7. Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?

    Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 14, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible

    PR Newswire ·

  8. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA)

    BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. KalVista Pharmaceuticals, Inc. (Nasdaq – KALV) Under the terms of the Merger Agreement, KalVista will be acquired by Chiesi Group for $27.00 per share in cash wi

    Globe Newswire ·

  9. Halper Sadeh LLC is Investigating Whether KALV, THR, CECO are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Halper

    Globe Newswire ·

  10. Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders?

    Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 8, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for o

    PR Newswire ·

  11. $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—BNCC, KALV, KW, and LEG

    NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde (https://www.globenewswire.com/Tracker?data=MiUov7JcIk0oBapI7M-Xa5qPKRjSw1QBBAYTg0vL1n1XHUq1_340uTy8U3QN33PQ-3-UQ9f8bIKwe_i67v3ScR065pXv6iKV7nxJZs_mHh95qsH8ZDGy-kDouDYEJy9aisEi5IQe6Hwy9xk-IDiwdIqhNzrF_u1YPLM_Y8sHbTnaYRnSh_xMkloIrRIAEsPrkhCxQ5KfUd9DhkF7Qoi4zw==) with Monteverde & Associates PC (https://www.globenewswire.com/Tracker?data=dK27_aSOG57N1J_5w1oN4DP8zfBL9EW15ZXg_3MNLpACpiPv8d-8wBMmH8SUs7FMW9fhatWT4yEHY6eOm

    Globe Newswire ·

  12. Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

    Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 4, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for o

    PR Newswire ·

  13. Are KALV, TBRG, UNF, ESQ Obtaining Fair Deals for their Shareholders?

    Are KALV, TBRG, UNF, ESQ Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 29, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsibl

    PR Newswire ·

  14. Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

    Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders PR Newswire MILWAUKEE, April 29, 2026 MILWAUKEE, April 29, 2026 /PRNewswire/ -- Ademi LLP is investigating KalVista (NASDAQ: KALV) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Chiesi Group. (https://mma.prnewswire.com/media/2672539/Ademi_Fruchter__Logo.html) Click here (https://edge.prnewswire.com/

    PR Newswire ·

  15. $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)

    NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde (https://www.globenewswire.com/Tracker?data=WXfS-UJCsyMXi3_8bQoz7-6Q2LqBY0RB-4ACl3th77MQ_Aa0xA4fRwq31tJ66nOlGDCyYSIOpa07ZyJO23WuEsm9aayhAMPcJhYTcrawOyhGAbqe4ZtbZ_0ao0OtXBvaF0E9wsE42RSKfzbT3n8hj13h01h30NeAWDaOJhr9I6Vpi1z27WWWmBiz80LonwxrgYc49T4wh85lRcMbB24nlA==) with Monteverde & Associates PC (https://www.globenewswire.com/Tracker?data=unsJfdOjubI8Yv-DdUvpRcDjLCBkwHdYQFk1GWj9J5EnZdOupQRYyNn0oYHDpw3Tmb4wTsHMVnqnMT

    Globe Newswire ·

  16. KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

    KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby

    Business Wire ·

  17. Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

    Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio Highlights: * Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn * Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions * Transaction expected to close in Q3 2026

    Business Wire ·

  18. KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375 shares of KalVista common stock on April 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing p

    Business Wire ·